- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT05850936
Effet de l'abaissement de la PIO sur le HM progressif (PHM)
Effet de la diminution médicale de la pression intraoculaire sur la forte myopie progressive
Currently, whether and when intraocular pressure (IOP) lowering medication should be used in progressive high myopia (HM) to control axial elongation is still a dilemma. Randomized trials are required to evaluate whether IOP lowering influences the growth of axial length in progressive HM eyes.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
Myopia has emerged as a major health issue in east Asia, especially the sight-threatening complications associated with high myopia (HM). Complication of HM can be associated with significant ocular morbidities including maculopathy, retinal detachment, and glaucoma.
Previous studies have shown that adult patients with HM have sustained growth of the axial length (AL), which is a risk factor for the progression of pathological myopia and thus may further affect the visual function , so how to slow down the sustained growth of the AL in adult patients with HM has become an urgent clinical problem. Previous studies have shown that IOP-lowering treatment is a protective factor for the growth of the AL in HM , and the results of animal experiments have further shown that medically IOP-lowering treatment can significantly slow down the AL lengthening and refractive changes in the guinea pig model of myopia. On this basis, the investigators proposed in a previous article that medically IOP-lowering treatment may slow down the growth of AL by three pathways related to the sclera and choroid: for the sclera, IOP-lowering treatment may reduce the scleral distending force, slow down the rate of scleral distension, and inhibit the activation of scleral fibroblasts to reduce scleral remodeling; for the choroid, IOP-lowering treatment may increase choroidal blood perfusion and for the choroid, hypotensive treatment can increase choroidal perfusion and thus reduce scleral remodeling due to scleral hypoxia. A previous retrospective study conducted by the investigators also shows that medically IOP-lowering treatment could control the progression of AL in HM, but there is still a lack of evidence from relevant robust randomized controlled clinical trials (RCT).
The investigators propose to conduct a RCT to evaluate whether medically IOP-lowering therapy is effective in controlling the progression of AL in HM. Secondly, this study also aims to provide data to evaluate IOP-lowering treatment effects on the incidence of changes in the visual field (VF), optic nerve head morphology including the retinal nerve fiber layer (RNFL), and retinal ganglion cell-inner plexiform layer (GC-IPL) loss, progression of myopic maculopathy, loss in visual function and change in quality of life. The outcomes of this study may provide a strong basis for treatment recommendations to control the progression of high myopic eyes, and to provide high-quality clinical research evidence for international clinical guidelines on myopia.
Type d'étude
Inscription (Estimé)
Phase
- N'est pas applicable
Contacts et emplacements
Lieux d'étude
-
-
Guangdong
-
Guangzhou, Guangdong, Chine, 510060
- Zhongshan Ophthalmic Center, Sun Yat-sen University
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Informed consent given, and consent form signed.
- Age between 18 and 65 years.
- Diagnosed with HM: spherical equivalent ≤ -6.00 diopters or AL ≥ 26.5 mm.
- Progressive HM: progression in AL ≥0.05mm in the past 6 months or ≥0.1mm in the past 12 months.
- IOP ≥ 10 mmHg and ≤ 21mmHg on at least 2 visits, as measured by Goldmann applanation tonometry .
- Best corrected visual acuity (BCVA) ≥ 6/12, and being able to obtain adequate AL examination, fundus photographs, optical coherence tomography (OCT) and complete the VF examination.
Exclusion Criteria:
- Allergic to any kind of IOP-lowering therapy.
- Combination of various serious fundus pathologies, such as proliferative diabetic retinopathy, retinal detachment, central retinal artery occlusion, etc.
- Combination of chronic, recurrent or severe ocular inflammatory lesions, such as chronic or recurrent uveitis.
- Patients with significant corneal or iris lesions, or severe cataract affecting fundus examination, or patients with only one eye.
- Patients who have undergone any surgery or laser treatment affecting eye parameters during the follow-up period (within the last 1 year), such as cataract surgery.
- Patients with other serious systemic diseases, such as hypertension, heart disease, diabetes, rheumatic immune system disease, etc., who cannot tolerate long-term follow-up and eye treatment.
- Pregnant or lactating women, or those who plan to have children during the follow-up period.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: La prévention
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Seul
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Intervention arm
medical reduction of IOP by eyedrops |
IOP-lowering eye drops Xalacom eyedrops (combination drops, fixed latanoprost with timolol) will be the choice for treatment. |
|
Aucune intervention: control arm
follow up without medication |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Annualized change in axial length (AL) from baseline to 12 months
Délai: 12 months
|
The cumulative change in AL from baseline to 12 months. |
12 months
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Annualized change in axial length (AL) from baseline to 24 months
Délai: 24 months
|
The cumulative change in AL from baseline to 24 months divided by 2 years. |
24 months
|
|
Annualized change in axial length (AL) from baseline to 36 months
Délai: 36 months
|
The cumulative change in AL from baseline to 36 months divided by 3 years. |
36 months
|
|
Change in spherical equivalent (SE) from baseline
Délai: 12, 24, and 36 months
|
Change in spherical equivalent refraction (SE) from baseline. |
12, 24, and 36 months
|
|
Change in intraocular pressure (IOP) from baseline
Délai: 12, 24, and 36 months
|
Change in intraocular pressure (IOP) from baseline |
12, 24, and 36 months
|
|
Change in choroidal thickness (ChT) from baseline
Délai: 12, 24, and 36 months
|
Change in subfoveal choroidal thickness (ChT) measured by OCT from baseline. |
12, 24, and 36 months
|
|
Change in visual field (VF) parameters and incidence/progression of VF defects
Délai: 12, 24, and 36 months
|
Change in Humphrey 24-2 mean deviation (MD) and pattern standard deviation (PSD) from baseline, and the incidence and progression of visual field defects |
12, 24, and 36 months
|
|
Change in retinal nerve fiber layer (RNFL) and ganglion cell-inner plexiform layer (GCIPL) thickness
Délai: 12, 24, and 36 months
|
Change in peripapillary RNFL and macular GCIPL thickness measured by OCT from baseline |
12, 24, and 36 months
|
|
Change in retinal and choroidal vascular parameters measured by OCTA
Délai: 12, 24, and 36 months
|
Change in vessel density of the superficial capillary plexus (SCP) and deep capillary plexus (DCP), and choriocapillaris (CC) flow metrics from baseline |
12, 24, and 36 months
|
|
Incidence of optic nerve head morphological changes
Délai: 12, 24, and 36 months
|
Incidence of morphological changes based on stereoscopic fundus photography, including increased cup-to-disc ratio, neuroretinal rim notching, wedge-shaped RNFL defects, or disc hemorrhage. |
12, 24, and 36 months
|
|
Incidence and progression of myopic maculopathy (MMD)
Délai: 12, 24, and 36 months
|
The incidence and progression rate of myopic maculopathy classified by the international photographic classification system. |
12, 24, and 36 months
|
|
Incidence and severity of adverse events (AEs) and serious adverse events (SAEs)
Délai: 1 month, 3 month, 6 month, 12 month, 24 month, 36 month
|
The incidence, severity, and relationship to study medication of all adverse events (AEs) and serious adverse events (SAEs) |
1 month, 3 month, 6 month, 12 month, 24 month, 36 month
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Chercheur principal: Xiulan Zhang, MD, PhD, Sun Yat-sen University
Publications et liens utiles
Publications générales
- Leske MC, Heijl A, Hyman L, Bengtsson B. Early Manifest Glaucoma Trial: design and baseline data. Ophthalmology. 1999 Nov;106(11):2144-53. doi: 10.1016/s0161-6420(99)90497-9.
- Leske MC, Hyman L, Hussein M, Heijl A, Bengtsson B. Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma. Am J Ophthalmol. 1999 May;127(5):625-6. No abstract available.
- Garway-Heath DF, Crabb DP, Bunce C, Lascaratos G, Amalfitano F, Anand N, Azuara-Blanco A, Bourne RR, Broadway DC, Cunliffe IA, Diamond JP, Fraser SG, Ho TA, Martin KR, McNaught AI, Negi A, Patel K, Russell RA, Shah A, Spry PG, Suzuki K, White ET, Wormald RP, Xing W, Zeyen TG. Latanoprost for open-angle glaucoma (UKGTS): a randomised, multicentre, placebo-controlled trial. Lancet. 2015 Apr 4;385(9975):1295-304. doi: 10.1016/S0140-6736(14)62111-5. Epub 2014 Dec 19.
- Jiang J, Lin T, Lin F, Kong K, Wang P, Song Y, Zhou F, Wang Z, Jin L, Liu Y, Gao X, Chen J, Chen M, Lam DSC, Jonas JB, Chen S, Zhang X; Glaucoma Suspects with High Myopia Study Group. Effect of intraocular pressure reduction on progressive high myopia (PHM study): study protocol of a randomised controlled trial. BMJ Open. 2024 Jun 5;14(6):e084068. doi: 10.1136/bmjopen-2024-084068.
Liens utiles
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Autres numéros d'identification d'étude
- 2023KYPJ110
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .